Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) presents significant treatment resistance challenges.
• Epidermal growth factor receptor (EGFR) targeted therapies, like Osimertinib, are crucial but face resistance.
• Novel therapeutic strategies are needed to overcome resistance in NSCLC treatment.

Purpose of the Study:

• To investigate Piperlongumine as a potential therapeutic agent to overcome Osimertinib resistance in NSCLC.
• To elucidate the molecular mechanisms by which Piperlongumine exerts its anti-cancer effects in NSCLC cells.
• To evaluate the efficacy of Piperlongumine in preclinical NSCLC models.

Main Methods:

• In vitro kinase assays to assess Piperlongumine's effect on EGFR activity.
• Apoptosis assays and Western blotting to analyze signaling pathways and protein expression.
• NSCLC xenograft models (Osimertinib-sensitive and resistant) to evaluate in vivo efficacy.

Main Results:

• Piperlongumine inhibited EGFR kinase activity in wild-type and resistant mutants.
• Piperlongumine induced intrinsic apoptosis by down-regulating Mcl-1 via the Akt-GSK3β pathway.
• Piperlongumine promoted Mcl-1 degradation through enhanced interaction with β-TRCP.
• Piperlongumine significantly inhibited tumor growth in both sensitive and resistant NSCLC xenografts.

Conclusions:

• Piperlongumine demonstrates potent anti-cancer activity against NSCLC, including Osimertinib-resistant forms.
• Piperlongumine overcomes EGFR-targeted therapy resistance by inducing Mcl-1 degradation and apoptosis.
• Piperlongumine holds significant potential for clinical application in NSCLC treatment, particularly for resistant cases.